FP 1039

Drug Profile

FP 1039

Alternative Names: Fibroblast growth factor ligand trap; FP-1039; GSK 3052230; HGS 1036

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Five Prime Therapeutics
  • Developer Five Prime Therapeutics; GlaxoSmithKline
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Type 1 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Mesothelioma; Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (IV, Infusion)
  • 08 Jun 2016 Efficacy and adverse events data from a phase I trial in Mesothelioma presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO- 2016)
  • 09 Sep 2015 Initial efficacy and adverse events data from a phase I trial in Non-small cell lung cancer and Mesothelioma released by Five Prime Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top